Language:

High-altitude illness

The Lancet (British edition), 2003-06, Vol.361 (9373), p.1967-1974 [Peer Reviewed Journal]

2003 Elsevier Ltd ;2003 INIST-CNRS ;Copyright Lancet Ltd. Jun 7, 2003 ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(03)13591-X ;PMID: 12801752 ;CODEN: LANCAO

Full text available

Citations Cited by

Actions
1. Add to My Research
2. Remove from My Research
3. E-mail
4. Print
5. Permalink
6. Citation
7. EasyBib
8. EndNote
9. RefWorks
10. Delicious
11. Export RIS
12. Export BibTeX

Title:
High-altitude illness
Author: Basnyat, Buddha ; Murdoch, David R
Subjects: Acetazolamide - therapeutic use ; Altitude ; Altitude Sickness - epidemiology ; Altitude Sickness - physiopathology ; Altitude Sickness - prevention & control ; Altitude Sickness - therapy ; Applied physiology ; Biological and medical sciences ; Brain Edema - etiology ; Brain Edema - therapy ; Epidemiology ; Ginkgo biloba ; Human physiology applied to population studies and life conditions. Human ecophysiology ; Humans ; Illnesses ; Medical sciences ; Pathology ; Phytotherapy ; Pulmonary Edema - etiology ; Pulmonary Edema - physiopathology ; Pulmonary Edema - therapy ; Risk Factors ; Transports. Aerospace. Diving. Altitude
Is Part Of: The Lancet (British edition), 2003-06, Vol.361 (9373), p.1967-1974
Description: High-altitude illness is the collective term for acute mountain sickness (AMS), high-altitude cerebral oedema (HACE), and high-altitude pulmonary oedema (HAPE). The pathophysiology of these syndromes is not completely understood, although studies have substantially contributed to the current understanding of several areas. These areas include the role and potential mechanisms of brain swelling in AMS and HACE, mechanisms accounting for exaggerated pulmonary hypertension in HAPE, and the role of inflammation and alveolar-fluid clearance in HAPE. Only limited information is available about the genetic basis of high-altitude illness, and no clear associations between gene polymorphisms and susceptibility have been discovered. Gradual ascent will always be the best strategy for preventing high-altitude illness, although chemoprophylaxis may be useful in some situations. Despite investigation of other agents, acetazolamide remains the preferred drug for preventing AMS. The next few years are likely to see many advances in the understanding of the causes and management of high-altitude illness.
Publisher: London: Elsevier Ltd
Language: English
Identifier: ISSN: 0140-6736
EISSN: 1474-547X
DOI: 10.1016/S0140-6736(03)13591-X
PMID: 12801752
CODEN: LANCAO
Source: ProQuest One Psychology
MEDLINE
ProQuest Central

Back to results list


INSPIRE LIBRARY - TON DUC THANG UNIVERSITY	(84-028) 37 755 057	Feedback
19 Nguyen Huu Tho St. Dist.7, HCM	thuvien@tdtu.edu.vn	Feedback

High-altitude illness

2003 Elsevier Ltd ;2003 INIST-CNRS ;Copyright Lancet Ltd. Jun 7, 2003 ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(03)13591-X ;PMID: 12801752 ;CODEN: LANCAO

Searching Remote Databases, Please Wait